CRNX - Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY.
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to a loss of $1.04 per share a year ago.
PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2026.
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics' first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly. “The European Commission's decision to approve Palsonify reflects the strength of the clinical data and marks a pivotal step toward bringing this important therapy to even more people living with acromegaly,” said Scott Struthers, Ph.D.
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX - Get Free Report) insider Jeff Knight sold 85,163 shares of the company's stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $40.10, for a total transaction of $3,415,036.30. Following the transaction, the insider owned 105,289 shares of the company's stock,
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation
A director of Crinetics Pharmaceuticals reported that he sold 5,000 shares of the company for a transaction value of approximately $180,761 on March 12, 2026. The sale represented 23.47% of Coelho's direct common stock holdings, reducing direct ownership from 21,300 to 16,300 shares.
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults. “The submission of our MAA for Palsonify in Brazil represents another important global milestone for this important therapy,” said Scott Struthers, Ph.D.
Executives from Crinetics Pharmaceuticals (NASDAQ: CRNX) used an investor discussion at TD Cowen's 46th Annual Healthcare Conference to highlight early U.S. commercial progress for its newly launched acromegaly drug, outline upcoming regulatory and clinical milestones, and describe how its pipeline is built around novel small-molecule therapies targeting G protein-coupled receptors (GPCRs). PALSONIFY launch: early demand, reimbursement
Intech Investment Management LLC lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 47.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,225 shares of the company's stock after selling 20,408 shares during the quarter. Intech Investment Management LLC's
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to a loss of $0.88 per share a year ago.
PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and eleven have issued a buy rating on the company. The average 1-year price objective
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46 th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern Time Webcast link HERE Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management will be available for 1x1 meetings with investors on Wednesday, March 11, 2026 The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at www.crinetics.com/events.
Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends. Profitability This table compares Crinetics Pharmaceuticals and Xenetic